Vertex to pay Editas up to $100M, plus hefty annual fee, for CRISPR license

Vertex Pharmaceuticals Inc. will pay a hefty price to a local competitor before it starts selling its newly approved sickle-cell treatment.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news